Floatz logo

Dipyridamole

Cerebrovascular Disorders

The Second Hospital of Anhui Medical UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Cerebrovascular Disorders cohort.

Asset / SponsorPhaseRating
Nicotine
Ottawa Heart Institute Research Corporation
Phase 4BB
Wellbutrin
Ottawa Heart Institute Research Corporation
Phase 4BB
Acetylsalicylic Acid
The Second Hospital of Anhui Medical University
Phase 3BB
Varenicline Tartrate
Ottawa Heart Institute Research Corporation
Phase 4BB
Tenecteplase
University of Melbourne
Phase 3BB

View all 19 →

Same molecule, other indications

Dipyridamole is also rated in:

venous thromboembolismDormant
BB
Indicative ·
71 / 100
View asset →
brain ischemiaDormant
BB
Indicative ·
68 / 100
View asset →
portal hypertensionDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →